Who makes [^13C4D3^15N]-baricitinib?

[^13C4D3^15N]-baricitinib is developed by Eli Lilly and Company.

What development phase is [^13C4D3^15N]-baricitinib in?

[^13C4D3^15N]-baricitinib is in Phase 1.

Last reviewed 2026-05-14 · How we verify

[^13C4D3^15N]-baricitinib

Eli Lilly and Company · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	[^13C4D3^15N]-baricitinib
Also known as	[^13C4D3^15N]-LY3009104
Sponsor	Eli Lilly and Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[^13C4D3^15N]-baricitinib CI brief — competitive landscape report
[^13C4D3^15N]-baricitinib updates RSS · CI watch RSS
Eli Lilly and Company portfolio CI